We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of vitamin D<sub>3</sub> vs. calcifediol on VDR concentration and fiber size in skeletal muscle.
- Authors
Ceglia, Lisa; Rivas, Donato A.; Schlögl, Mathias; Fielding, Grace B.; Egli, Andreas; Bischoff-Ferrari, Heike A.; Dawson-Hughes, Bess
- Abstract
Introduction: This study sought to examine the effect of vitamin D3 (VD3) 3200 IU/d, calcifediol (HyD) 20mcg/d, or placebo on intramyonuclear vitamin D receptor (VDR) concentration, muscle fiber cross-sectional area (FCSA), and muscle satellite cell activation. Materials and methods: It was conducted on a subset of the VD3 (n = 12), HyD (n = 11), and placebo (n = 13) groups who participated in the 6-month randomized controlled HyD Osteopenia Study in postmenopausal women. Baseline and 6-month vastus lateralis muscle cross sections were probed for VDR, fiber type I and II, and PAX7 (satellite cell marker) using immunofluorescence. Results: Baseline mean ± SD age was 61 ± 4 years and serum 25-hydroxyvitamin D (25OHD) level was 55.1 ± 22.8 nmol/L. Baseline characteristics did not differ significantly by group. Six-month mean ± SD 25OHD levels were 138.7 ± 22.2 nmol/L (VD3), 206.8 ± 68.8 nmol/L (HyD), and 82.7 ± 36.1 nmol/L (placebo), ANOVA P < 0.001. There were no significant group differences in 6-month change in VDR concentration (ANOVA P = 0.227). Mean ± SD percent 6-month changes in type I FCSA were 20.5 ± 32.7% (VD3), − 6.6 ± 20.4% (HyD), and − 0.3 ± 14.0% (placebo, ANOVA P = 0.022). Type II FCSA or PAX7 concentration did not change significantly by group (all P > 0.358). Conclusion: This study demonstrated no significant change in intramyonuclear VDR in response to either form of vitamin D vs. placebo. Type I FCSA significantly increased with VD3, but not with HyD at 6 months. As type I fibers are more fatigue resistant than type II, enlargement in type I suggests potential for improved muscle endurance. Although HyD resulted in the highest 25OHD levels, no skeletal muscle benefits were noted at these high levels. Clinical trial: NCT02527668.
- Subjects
CALCIFEDIOL; VITAMIN D receptors; VITAMINS; VASTUS lateralis; SATELLITE cells; MUSCLE fatigue
- Publication
Journal of Bone & Mineral Metabolism, 2023, Vol 41, Issue 1, p41
- ISSN
0914-8779
- Publication type
Article
- DOI
10.1007/s00774-022-01374-y